Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platelet mass cytometry reveals dysregulation of prothrombotic pathways in essential thrombocythemia.
Dill V, Kirmes K, Han J, Klug M, Rosenbaum M, Viggiani G, von Scheidt M, List M, Herhaus P, Ruland J, Bassermann F, Laugwitz KL, Götze KS, Jost PJ, Jilg S, Bloxham CJ, Raake PWJ, Bernlochner I, Bongiovanni D. Dill V, et al. Among authors: gotze ks. Platelets. 2024 Dec;35(1):2358244. doi: 10.1080/09537104.2024.2358244. Epub 2024 Jun 7. Platelets. 2024. PMID: 38845541 Free article.
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche.
Winter S, Götze KS, Hecker JS, Metzeler KH, Guezguez B, Woods K, Medyouf H, Schäffer A, Schmitz M, Wehner R, Glauche I, Roeder I, Rauner M, Hofbauer LC, Platzbecker U. Winter S, et al. Among authors: gotze ks. Leukemia. 2024 May;38(5):936-946. doi: 10.1038/s41375-024-02226-6. Epub 2024 Mar 21. Leukemia. 2024. PMID: 38514772 Free PMC article. Review.
Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells.
Rothfuß C, Baumann T, Donakonda S, Brauchle B, Marcinek A, Urban C, Mergner J, Pedde AM, Hirschberger A, Krupka C, Neumann AS, Hänel G, Merten C, Öllinger R, Hecker JS, Bauer T, Schmid CR, Götze KS, Altomonte J, Bücklein VL, Jacobs R, Rad R, Dawid C, Simeoni L, Schraven B, Pichlmair A, Subklewe M, Knolle PA, Böttcher JP, Höchst B. Rothfuß C, et al. Among authors: gotze ks. Blood. 2025 Jan 21:blood.2024025706. doi: 10.1182/blood.2024025706. Online ahead of print. Blood. 2025. PMID: 39840945
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M. Shahswar R, et al. Among authors: gotze ks. Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501-6. Online ahead of print. Leukemia. 2025. PMID: 39779979
CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia.
Braitsch K, Lorenzini T, Hefter M, Koch K, Nickel K, Peeken JC, Götze KS, Weber W, Allmann A, D'Alessandria C, Brosch-Lenz J, Bassermann F, Rudelius M, Verbeek M, Eiber M, Herhaus P. Braitsch K, et al. Among authors: gotze ks. Theranostics. 2025 Jan 1;15(1):19-29. doi: 10.7150/thno.101215. eCollection 2025. Theranostics. 2025. PMID: 39744224 Free PMC article.
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Bresser H, et al. Among authors: gotze ks. Eur J Haematol. 2025 Feb;114(2):231-237. doi: 10.1111/ejh.14304. Epub 2024 Oct 13. Eur J Haematol. 2025. PMID: 39400388 Free PMC article. Clinical Trial.
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider I, Corbacioglu A, Gaidzik VI, Meid A, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Rücker FG, et al. Among authors: gotze ks. Blood Adv. 2024 Dec 10;8(23):6067-6080. doi: 10.1182/bloodadvances.2024013758. Blood Adv. 2024. PMID: 39348668 Free PMC article.
99 results